The problem
The scientific research community faces challenges in conducting efficient, high-quality systematic literature reviews due to the overwhelming volume of data, time-intensive processes, and the need for up-to-date information.
The solution
The startup leads in AI-driven solutions for systematic reviews, with a unique approach that focuses on optimizing processes within Publication Research Tools, especially in the pharmaceutical and medtech industries.
USP
The solution addresses the challenges of time-consuming systematic reviews in publication research. The technology accelerates the process and enhances decision-making in the research and product regulation environment.
Customers
Primary target audiences include academic institutions, pharmaceutical companies, and organizations within legal patent domains.
The ambition
The ambition is to revolutionize systematic reviews, achieve market dominance in the pharmaceutical and medtech industries, on a global scale.
The team
A – CEO with 23 years of experience as R&D coordinator and innovation consultant.
B – CTO with extensive experience in AI and ML technologies, with in-depth expertise in Generative AI solutions.
Status
Co-op with 33 key scientists, who have conducted thorough analyses on how to establish systematic overviews and have identified gaps in existing solutions. Of those 33, 17 have decided to become testusers. The concept has been introduced to the 17 users who are all very positive and will continue to review future iterations of the solution.
Finance
The startup is currently aiming to raise soft money, in order to finalize development of the platform. Furthermore, they are working to establish a consortium in the EU aiming to review the impact of their solution in comparison to existing solutions.
Next step
Aiming to have the first product ready in 6 months, priced at EUR 300, enabling users to write and publish protocols for systematic reviews. 2nd product to be ready in 12 months, priced at EUR 7-8,000, enabling users to fully review articles for publication.